Trial
NCT04404140
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Castration-Resistant Prostatic Cancer
Intervention
Ipatasertib
Why stopped
Despite many risk-minimization strategies, the combination of ipatasertib, atezolizumab and docetaxel was challenging due to multiple study treatment modifications required to manage toxicity, making further enrollment inappropriate.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-17